research Topical Bimatoprost (0.03%) Versus Topical Mometasone Furoate (0.1%) in Treatment of Alopecia Areata
Mometasone furoate cream was more effective than bimatoprost solution for treating hair loss from Alopecia Areata.
Search
for
Sort by
Research
270-300 / 1000+ results research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
research 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials
Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
research Finasteride.
research Diphencyprone in the treatment of Satoyoshi syndrome
Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Hypertrichosis of the eyelashes caused by bimatoprost
Bimatoprost can cause excessive eyelash growth.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Microneedles self-implanting Astragalus polysaccharides-hybridized composite hydrogel combined with minoxidil to enhance in situ anti-androgenetic alopecia.
Microneedles with Astragalus and minoxidil improve hair growth.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK /STAT inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research Severe pustular lesions induced by topical immunotherapy with squaric acid dibutylester for alopecia totalis
Squaric acid dibutylester can cause severe skin reactions in people with allergies.
research Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
research RETRACTED: Genetic association between asthma and alopecia areata: A two‐sample Mendelian randomization study
Asthma may increase the risk of alopecia areata.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of FP-receptor activation
Topical latanoprost acid at 0.05% concentration improved hair growth in women with androgenetic alopecia.
research Bimatoprost Topical
Latisse (bimatoprost 0.03%) is widely used in dermatology but the document doesn't give detailed evidence or numbers.
research Bimatoprost in the treatment of eyelash hypotrichosis
Bimatoprost effectively enhances eyelash growth but may not work for all eyelash loss conditions.
research Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
research Ruxolitinib found to cause eyelash growth: a case report
Ruxolitinib treatment may cause eyelash growth.
research Upadacitinib for Alopecia: Current Evidence and Clinical Insights
Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research Mechanism of astragaloside A against lung adenocarcinoma based on network pharmacology combined with molecular dynamics simulation technique
Astragaloside A may help fight lung cancer by targeting specific proteins.
research RU 58841, a new specific topical antiandrogen: A candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism
RU 58841 may treat acne, hair loss, and excessive hair growth.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research EPH39 Alopecia Areata: Targeted Review of Adverse Events Associated with Clinical Studies of Treatments
Alopecia areata treatments often cause headaches and infections, highlighting the need for safer options.
research Dutasteride for Androgenetic Alopecia—Words of Caution
Dutasteride's effect on hair loss treatment is uncertain and should be used cautiously.
research Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review
Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
research Formestane Preferred as Second-Line Therapy in Advanced Breast Cancer
Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.